**PBS Transparency and Efficiencies Subgroup**

**Communique**

**January – June 2020**

The PBS Transparency and Efficiencies Subgroup met in January, March and April during the first half of 2020. Attendees included representatives from the Generic and Biosimilar Medicines Association (GBMA), Medicines Australia (MA), industry and the Department of Health (the department).

The department provided regular updates on the Health Product Portal’s current functionality and what is under development.

Members noted the department was revising the Public Summary Document (PSD) Procedure Guidance based on feedback from the July and November 2019 pilots. The Guidance was published in April 2020. The third and final March 2020 pilot of the final guidance will assess completeness and useability of the information. Medicines Australia will monitor implementation of the new PSD redaction criteria for any issues or unintended consequences for 12 months post‑implementation.

Members discussed the February cost recovery consultation webinar, which outlined the stage 2 streamlining process improvements supporting cost recovery. Members discussed that without government approval to implement Stage 2 PBS process improvements, the existing processes and 2020-21 fees included in the 2019-20 CRIS would apply. Members noted updates via the PBS website, and public consultation on the 2020-21 CRIS would occur as soon as possible.

The PBS Transparency and Efficiencies Subgroup will continue to meet throughout 2020 as needed.